Priovant

Pre-Approval PRO BETA

Total Trials

Phase 3

Phase 2

Recruiting

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Dermatomyositis Lichen Planopilaris Uveitis, Posterior Uveitis, Intermediate Uveitis

NCT06431373 Phase 3 ACTIVE NOT RECRUITING

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Started: 9/11/2024

NCT05437263 Phase 3 ACTIVE NOT RECRUITING

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

Started: 10/31/2022

NCT07532603 Phase 2 RECRUITING

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

Started: 3/19/2026

NCT06978725 Phase 2 RECRUITING

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Started: 4/9/2025

NCT05523765 Phase 2 COMPLETED

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

Started: 11/14/2022

NCT06433999 Phase 2 COMPLETED

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Started: 8/28/2024

Oral Brepocitinib Placebo Brepocitinib PO QD Placebo PO QD Brepocitinib Oral Placebo

Activity Status: Active

Last Trial Started: 3/19/2026

Last Trial Ended: 2/28/2025

Trials (12 months): 1

Completed Trials: 2

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.